Q-omics provides the consensus-scored FTH1 profile across patient tissues and cancer cell-line models. FTH1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, FTH1 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, FTH1 protein abundance shows 21,819 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, HNSC, and LSCC as cancer lineages where FTH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FTH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FTH1 survival associations across molecular data types. FTH1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FTH1 RNA expression–survival associations across cancer types. High FTH1 expression shows unfavorable associations in KICH, HNSC, UVM, KIRP, LIHC and LGG. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for FTH1 RNA expression.
This table summarizes FTH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FTH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FTH1 shows lower tumor expression in COAD and LUAD and higher tumor expression in HNSC, KIRC, LIHC and KIRP. The HNSC box plot shows higher FTH1 RNA expression in tumor versus normal tissue (log2 FC = +1.515, t-test p < 0.001).
This table shows molecular features associated with FTH1 in patient tissues and cancer cell lines. In patient samples, FTH1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FTH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
